Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.
First-line treatment with olaparib for early stage BRCA-positive ovarian cancer: may it be possible? Hypothesis potentially generating a line of research / Tomao, F.; Boccia, S. M.; Chirra, M.; Palaia, I.; Petrella, M. C.; Di Donato, V.; Colombo, N.; Panici, P. B.; Sassu, C. M.. - In: CANCER MANAGEMENT AND RESEARCH. - ISSN 1179-1322. - 12:(2020), pp. 5479-5489. [10.2147/CMAR.S194874]
First-line treatment with olaparib for early stage BRCA-positive ovarian cancer: may it be possible? Hypothesis potentially generating a line of research
Tomao F.Primo
Conceptualization
;Boccia S. M.;Palaia I.;Petrella M. C.;Di Donato V.;Panici P. B.;
2020
Abstract
Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tomao_Ovarian-cancer_2020.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
542.51 kB
Formato
Adobe PDF
|
542.51 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
